LIXTE Biotechnology Pivots to AI Energy Infrastructure, Shares Slip 6%

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform focused on meeting the rapidly growing power demands of AI and hyperscale data centers. Following the announcement, the company's shares slipped 5.78 percent to $5.89, down $0.36, on the Nasdaq. The stock opened at $6.45 and traded between $5.80 and $6.50 during the session, with volume of 497,407 shares compared with the average daily volume of 59,433 shares. LIXTE shares have traded between $0.64 and $6.50 over the past 52 weeks.

The transformation comes amid a widening gap between North American electricity demand and available generation capacity, driven largely by the rapid expansion of AI and hyperscale data centers. In its January 2026 Long-Term Reliability Assessment, the North American Electric Reliability Corporation (NERC) projected summer peak demand will increase by 224 gigawatts over the next decade while warning that several major grid regions face elevated risk of supply shortfalls. In April 2026, NERC issued a rare Level 3 Alert directing grid operators to address reliability risks tied to large-scale computational loads.

"The power problem is the AI problem," said the chief executive officer of LIXTE. "Compute capacity is being built faster than the grid can support it. Hyperscale operators, sovereign AI programs and next-generation inference applications all face the same constraint: reliable power. We believe LIXTE is positioned to become a focused public-market platform addressing that challenge by helping debottleneck the power infrastructure." LIXTE's strategy will focus on power equipment and service solutions for hyperscale AI and data-center campuses, including long-duration generation, co-located power assets and grid-edge infrastructure; equipment for distributed and behind-the-meter power systems supporting enterprise AI, sovereign compute and edge inference deployments; and strategic acquisitions and partnerships targeting advanced generation technologies. LIXTE expects to maintain its Nasdaq listing under the ticker symbol "LIXT" during the transformation process.

In connection with the transformation, the founder, managing partner, chief executive officer and chief investment officer of Denham Capital Management LP will join the Company's Board of Directors. Denham Capital was founded in 2004 and has overseen more than $12 billion of invested and committed capital across the energy and energy-transition sectors. Its infrastructure group is advancing a U.S. and European pipeline of roughly 10 GW of AI data-center-oriented power generation asset opportunities to support the data center buildout, drawing on its deep execution experience in developing, building and financing large-scale gas, renewable and storage projects globally. "This is a generational dislocation between compute demand and reliable, dispatchable power," said the incoming director. "The anticipated AI build-out will require disciplined capital allocation, operational execution and long-duration infrastructure investment."

The Company also announced it will seek a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on advancing cancer treatments. LIXTE is a clinical-stage biopharmaceutical company focused on cancer drug development, with a pipeline centered on inhibitors of protein phosphatase 2A (PP2A). Its lead clinical candidate, LB-100, is a first-in-class small-molecule PP2A inhibitor that has demonstrated anti-cancer activity in clinical settings and has been shown to be well-tolerated in cancer patients at doses associated with anti-cancer activity. Proof-of-concept clinical trials of LB-100 are in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma, with collaborations including The University of Texas MD Anderson Cancer Center, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Netherlands Cancer Institute, with support from GSK and F. Hoffmann-La Roche.

LIXTE recently outlined advances in its approach to cancer therapy through LB-100, which works by inhibiting PP2A, an enzyme involved in cell growth regulation, DNA repair and immune modulation. The company is also sponsoring the Good Health: Mind, Body & Soul Summit, a health and wellness event focused on addressing disparities in care.

In addition to its pharmaceutical activities, LIXTE has disclosed a corporate initiative to diversify its treasury. The company's Board of Directors approved a capital allocation policy allowing a portion of its treasury to be held in cryptocurrencies, including Bitcoin and Ethereum, and the company executed an initial purchase of digital currencies as part of this policy. LIXTE has also completed private placements and registered direct offerings of common stock, preferred stock and warrants, using proceeds for general corporate purposes and working capital, including support for ongoing clinical trials. The company reported that these financings contributed to regaining compliance with Nasdaq's continued listing requirements.